NEW CANCER TREATMENTS

摘要

The invention relates to a product comprised of specific combinations of cell lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in humans. The heterogeneity of the immunotherapeutic matches the heterogeneity of the antigenic profile in the target cancer and immunises the recipients with many of the potential TAA and TSA which are expressed at various stages of the disease. The invention discloses a two part product comprising as first part: a single cell line used for the first two to five administrations; and a second part which is a mixture of three different of the cell lines which may or may not include the single cell line used in the first part, used for subsequent vaccinations. Cell lines may be prepared from cancer biopsy material using techniques known to those skilled in the art. In the case of prostate cancer, for example, cell lines may be prepared from primary or metastatic prostate cancer biopsy material. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent.